Cell Source, Inc. (CLCS) shareholders
CLCSOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2025, quý kết thúc ngày Mar 31, 2025Last filing: 10-Q on May 14, 2026
$0.49−0.00 (-0.01%)
Close on Oct 19, 2026Market cap $21.99MP/E –Yield –
Ownership
Who owns Cell Source's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Zolty Director | Jun 30, 2021 | Other | +4,860 | $0.75 | $3.65K | 1,127,504 |
| Darlene Soave Director, 10% owner | Jun 30, 2021 | Other | +59,507 | $0.75 | $44.63K | 174,434 |
| Dennis M. Brown Director | Jun 30, 2021 | Other | +2,976 | $0.75 | $2.23K | 114,927 |
| Benzion Abraham Friedman Director, 10% owner | Jun 30, 2021 | Other | +19,440 | $0.75 | $14.58K | 4,408,184 |
| Benzion Abraham Friedman Director, 10% owner | Dec 29, 2020 | Other | +19,672 | $0.75 | $14.75K | 4,471,200 |
| David Zolty Director | Dec 29, 2020 | Other | +4,941 | $0.75 | $3.71K | 1,117,784 |
| Dennis M. Brown Director | Dec 29, 2020 | Other | +3,025 | $0.75 | $2.27K | 111,951 |
| Benzion Abraham Friedman Director, 10% owner | Jun 30, 2020 | Other | +19,547 | $0.75 | $14.66K | 4,451,438 |
| David Zolty Director | Jun 30, 2020 | Other | +4,887 | $0.75 | $3.67K | 1,112,843 |
| Dennis M. Brown Director | Jun 30, 2020 | Other | +2,992 | $0.75 | $2.24K | 108,926 |
| Benzion Abraham Friedman Director, 10% owner | Dec 31, 2019 | Other | +25,675 | $0.75 | $19.26K | 4,431,891 |
| David Zolty Director | Dec 31, 2019 | Other | +6,420 | $0.75 | $4.82K | 1,107,956 |
| Dennis M. Brown Director | Dec 31, 2019 | Other | +5,934 | $0.75 | $4.45K | 105,934 |
| Benzion Abraham Friedman Director, 10% owner | Jun 26, 2019 | Other | +5,356 | $0.75 | $4.02K | 4,406,216 |
| David Zolty Director | Jun 26, 2019 | Other | +1,339 | $0.75 | $1.00K | 1,101,536 |
| Benzion Abraham Friedman Director, 10% owner | Dec 31, 2018 | Other | +5,444 | $0.75 | $4.08K | 4,400,860 |
| David Zolty Director | Dec 31, 2018 | Other | +1,361 | $0.75 | $1.02K | 1,100,197 |
| Benzion Abraham Friedman Director, 10% owner | Aug 21, 2018 | Other | +6,672 | $0.75 | $5.00K | 4,395,416 |
| David Zolty Director | Aug 21, 2018 | Other | +1,668 | $0.75 | $1.25K | 1,098,836 |
| Benzion Abraham Friedman Director, 10% owner | Dec 4, 2017 | Other | +5,400 | $0.75 | $4.05K | 4,388,744 |
| David Zolty Director | Dec 4, 2017 | Other | +1,350 | $0.75 | $1.01K | 1,097,168 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.1
At 0M shares a day
Change since last report
-32.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cell Source's stock actually held short. Settlement fails (shares not delivered on time) peaked at 915 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?